Galapagos PE Ratio 2013-2021 | GLPG

Current and historical p/e ratio for Galapagos (GLPG) from 2013 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Galapagos PE ratio as of October 22, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Galapagos PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-22 50.93 0.00
2021-06-30 68.89 $-2.47 0.00
2021-03-31 77.09 $-3.24 0.00
2020-12-31 98.98 $-4.27 0.00
2020-09-30 141.91 $-6.60 0.00
2020-06-30 197.29 $1.56 126.47
2020-03-31 195.92 $2.54 77.13
2019-12-31 206.83 $2.39 86.54
2019-09-30 152.66 $5.06 30.17
2019-06-30 128.93 $-1.31 0.00
2019-03-31 117.78 $-0.84 0.00
2018-12-31 91.74 $-0.73 0.00
2018-09-30 112.43 $-1.07 0.00
2018-06-30 92.18 $-1.71 0.00
2018-03-31 99.76 $-0.34 0.00
2017-09-30 101.75 $-1.15 0.00
2017-03-31 86.19 $-1.95 0.00
2016-03-31 41.82 $-2.29 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.337B $0.606B
Galapagos NV is a biotechnology company. The Company's operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include GLPG0634 for the treatment of rheumatoid arthritis and other inflammatory diseases, GLPG1205/GLPG1690 for treating inflammatory bowel disease, GSK2586184 for the treatment of chronic immuno-inflammatory diseases and GLPG0974, to prevent free fatty acid-induced activation and migration of neutrophils which are in different clinical trial. Galapagos NV is headquartered in Mechelen, Belgium.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76